The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

Part of paid clinical trials in Farmington, Connecticut.

Sponsor
UConn Health
Study ID
NCT06027554
Phase
PHASE2
Status
Recruiting

Conditions

  • Aging
  • Frailty
  • Mild Cognitive Impairment

Eligibility Criteria

Sex
ALL
Age
65 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Mitoquinone Mesylate — DRUG
    MitoQ given 20 mg per day for 12 weeks.
  • Placebo capsule — DIETARY_SUPPLEMENT
    Placebo capsule taken every day for 12 weeks.

Study Details

The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.

Key Dates

Start date
Oct 7, 2024
Status verified
Jan 2025
Primary completion
Mar 1, 2027
Completion
Feb 1, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo capsule
    Gelatin capsules
  • Experimental: MitoQ capsule
    Capsules containing mitoquinone mesylate (MitoQ, 5 mg/capsule) totaling 20 mg taken every day for 12 weeks.

Primary Outcome Measure

Change in Vascular Endothelial Function [ Time Frame: 4 visits : Baseline, 12 weeks (MitoQ or Placebo), 8 weeks washout, 12 weeks (MitoQ or Placebo) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UConn HealthFarmingtonConnecticut06030
George Kuchel, MD
860-679-6796

Find similar trials in Farmington, CT

Related Studies